Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 12/18/2024 at 16:00, 1 year 6 months ago

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Jaguar Health, Inc. initiates Phase 2 study for crofelemer, a novel plant-based drug, in pediatric MVID patients. Study aims to evaluate drug efficacy for rare diseases MVID and SBS-IF

Crofelemer Jaguar Health Inc. Phase 2 Study Pediatric Patients MVID
BRIEF

published on 12/17/2024 at 14:35, 1 year 6 months ago

FDA Grants Orphan-Drug Designation to Jaguar Health's Crofelemer for Cholera

Crofelemer FDA Approval Jaguar Health Orphan-Drug Designation Cholera Treatment
BRIEF

published on 12/17/2024 at 14:35, 1 year 6 months ago

La FDA accorde la désignation de médicament orphelin au Crofelemer de Jaguar Health pour le traitement du choléra

Crofelemer Désignation De Médicament Orphelin Approbation De La FDA Santé Jaguar Traitement Du Choléra
PRESS RELEASE

published on 12/17/2024 at 14:30, 1 year 6 months ago

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
World Health Organization (WHO) elevates cholera to highest emergency level due to global resurgence. Crofelemer granted orphan-drug designation by FDA and EMA for cholera treatment

FDA Crofelemer Cholera Orphan-Drug Designation World Health Organization
BRIEF

published on 12/13/2024 at 16:05, 1 year 6 months ago

Ladenburg Thalmann to Host Scientific Showcase on Jaguar Health's Crofelemer

Crofelemer Jaguar Health Rare Diseases Napo Therapeutics Scientific Showcase
BRIEF

published on 12/13/2024 at 16:05, 1 year 6 months ago

Ladenburg Thalmann organise une exposition scientifique sur le Crofelemer de Jaguar Health

Crofelemer Maladies Rares Santé Jaguar Napo Thérapeutique Vitrine Scientifique
PRESS RELEASE

published on 12/13/2024 at 16:00, 1 year 6 months ago

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Jaguar Health, Inc. announces virtual event on crofelemer clinical development efforts for rare diseases MVID and SBS-IF. CEO awarded 'Best CEO BioPharmaceuticals of the Year'

Crofelemer Clinical Development Jaguar Health Rare Diseases MVID
BRIEF

published on 12/12/2024 at 15:05, 1 year 6 months ago

Jaguar Health's Crofelemer Shows Promise in Treating Cancer Therapy-Related Diarrhea

Crofelemer Cancer Therapy-related Diarrhea Clinical Trial Breast Cancer SABCS
BRIEF

published on 12/12/2024 at 15:05, 1 year 6 months ago

Le Crofelemer de Jaguar Health s'avère prometteur dans le traitement de la diarrhée liée à la thérapie contre le cancer

Crofelemer Essai Clinique Cancer Du Sein Diarrhée Liée Au Traitement Du Cancer SABCS
PRESS RELEASE

published on 12/12/2024 at 15:00, 1 year 6 months ago

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals presents statistically significant results of crofelemer in breast cancer patients for prophylaxis of CTD at SABCS. Study highlights impact of diarrhea in cancer treatment

Napo Pharmaceuticals Crofelemer Breast Cancer CTD SABCS

Published on 06/27/2026 at 01:40, 6 hours 8 minutes ago

Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 7 hours 48 minutes ago

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 8 hours 48 minutes ago

Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 8 hours 58 minutes ago

Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 9 hours 33 minutes ago

Revive Therapeutics Announces Proposed Private Placement

View all ACCESSWIRE

Published on 06/27/2026 at 00:05, 7 hours 43 minutes ago

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 7 hours 44 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 8 hours 12 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 8 hours 12 minutes ago

EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 8 hours 20 minutes ago

EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE

View all EQS

Published on 06/26/2026 at 17:45, 14 hours 3 minutes ago

Combined General Meeting, June 25, 2026
Published on 06/26/2026 at 17:45, 14 hours 3 minutes ago

Assemblée générale mixte du 25 juin 2026
Published on 06/26/2026 at 17:45, 14 hours 3 minutes ago

Descriptif du programme de rachat d'actions
Published on 06/26/2026 at 14:44, 17 hours 4 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 17 hours 4 minutes ago

Information Safran

View all LES ECHOS COMFI WIRE

News